Explore / Clinical trial
Clinical trial

Study of Immunomodulation Using Naltrexone and Ketamine for COVID-19

Corewell Health EastTerminatedPhase 2Started Apr 29, 202070 enrolledUnited StatesNCT04365985

Abstract

Ideal new treatments for Novel Coronavirus-19 (COVID-19) would help halt the progression disease in patients with mild disease prior to the need for artificial respiration (ventilators), and also provide a rescue treatment for patients with severe disease, while also being affordable and available in quantities sufficient to treat large numbers of infected people. Low doses of Naltrexone, a drug approved for treating alcoholism and opiate addiction, as well as Ketamine, a drug approved as an anesthetic, may be able to interrupt the inflammation that causes the worst COVID-19 symptoms and prove an effective new treatment. This study will investigate their effectiveness in a randomized, blinded trial versus standard treatment plus placebo.

Topics & conditions

Detected automatically by Psychedelic Commons from the title and abstract, not labels from the source. They may be incomplete.

KetamineAddiction

Keywords

naltrexonecytokine stormInterleukin-2therapeutic treatmentCOVID-19Acute Respiratory Distress SyndromeSevere Acute Respiratory Syndrome (SARS)Coronavirus Infections

Psychedelic Commons aggregates metadata from open sources and links back to the original. Rights remain with the authors and publishers. Something wrong with this record? Report a problem.